HTA

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

Market Access

Beyond the Bill: how do we make medicines affordable without...

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

Market Access

Early strategic evidence planning is a key success factor in...

As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.

Market Access

One in five expressions of interest in UK regulator's pilot ...

The MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence scientific dialogue programme.

Market Access

Is money the only metric that really matters in UK’s VPAG? I...

The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.

Digital

Health Technology Assessment – Challenges and opportunities ...

Changes to Health Technology Assessment in Europe offer new opportunities to streamline processes and get innovative treatments to market faster

Request to look further into NICE non-submissions in the fut...

Beyond the Bill: how do we make medicines affordable without...

Early strategic evidence planning is a key success factor in...

One in five expressions of interest in UK regulator's pilot ...

Is money the only metric that really matters in UK’s VPAG? I...

Health Technology Assessment – Challenges and opportunities ...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

HTA

Editor's Picks